Why the study?
Does atenolol/chlorthalidone reduce blood pressure and is it well-tolerated in ambulatory patients with arterial hypertension?
Does atenolol/chlorthalidone reduce blood pressure and is it well-tolerated in ambulatory patients with arterial hypertension?
Atenolol/chlorthalidone combination therapy effectively reduces blood pressure and is well-tolerated in ambulatory patients with arterial hypertension.
Atenolol/chlorthalidone was associated with short-term BP reduction; leaves open confirmation of tolerability and outcomes in randomized trials.
A post-marketing clinical trial was carried out in ambulatory patients to assess the efficacy and toleration of atenolol (100 mg)/chlorthalidone (25 mg) tablets in the treatment of arterial hypertension. Data are reported on a cut-off at 2449 patients. Analysis of results in the different age groups has shown that after 4 weeks of treatment there was a mean fall of 16-17% in systolic and of 16-18% in diastolic blood pressure. Adequate blood pressure reduction was obtained for all age groups. The frequency of adverse reactions/events was low, these being reported in only 5.7% of cases. As discontinuation of treatment on account of adverse reactions/events occurred in 3.8% of patients, the risk-to-benefit relationship of atenolol/chlorthalidone tablets was very favourable.
No takes yet. Share an insight, caveat, or question.
Emanueli et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: